| scholarly article | Q13442814 |
| P50 | author | Richard S. Legro | Q40316671 |
| Ricardo Azziz | Q50085674 | ||
| P2093 | author name string | Kristen Kasza | |
| David A Ehrmann | |||
| David R Liljenquist | |||
| Mahmoud N Ghazzi | |||
| PCOS/Troglitazone Study Group | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | polycystic ovary syndrome | Q500816 |
| metabolic syndrome | Q657193 | ||
| polycystic ovary | Q5547896 | ||
| P304 | page(s) | 48-53 | |
| P577 | publication date | 2005-10-25 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome | |
| P478 | volume | 91 |
| Q38862193 | A case-control study on reduced HDL2b in patients with polycystic ovarian syndrome |
| Q61451147 | Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial |
| Q37648474 | Acute hypertriglyceridemia induces platelet hyperactivity that is not attenuated by insulin in polycystic ovary syndrome |
| Q89793745 | Adipose Insulin Resistance and Circulating Betatrophin Levels in Women with PCOS |
| Q36593148 | Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child. |
| Q46484480 | Age-related differences in the reproductive and metabolic implications of polycystic ovarian syndrome: findings in an obese, United States population |
| Q30433940 | Androgen receptor antagonism and an insulin sensitizer block the advancement of vaginal opening by high-fat diet in mice |
| Q45918351 | Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. |
| Q37199279 | Application of receiver operating characteristic curve in the assessment of the value of body mass index, waist circumference and percentage of body fat in the Diagnosis of Polycystic Ovary Syndrome in childbearing women |
| Q36648347 | Association between metabolic syndrome and premicroalbuminuria among Iranian women with Polycystic Ovary Syndrome: a case control study. |
| Q44640429 | Association between β2-adrenoceptor (ADRB2) haplotypes and insulin resistance in PCOS. |
| Q30423757 | Association of fibrillin-3 and transcription factor-7-like 2 gene variants with metabolic phenotypes in PCOS. |
| Q31060630 | Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study |
| Q46751800 | Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome. |
| Q35627388 | Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome |
| Q46237196 | Association of metabolic syndrome in polycystic ovarian syndrome: an observational study |
| Q41116375 | Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy |
| Q47417124 | Association study of HNF1A in women with polycystic ovary syndrome |
| Q87398077 | Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients |
| Q42756479 | Body Mass Index below Obesity Threshold Implies Similar Cardiovascular Risk among Various Polycystic Ovary Syndrome Phenotypes |
| Q34612878 | Brachial artery conductance during reactive hyperemia is increased in women with polycystic ovary syndrome |
| Q37437244 | C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome |
| Q53082778 | Calprotectin is a potential prognostic marker for polycystic ovary syndrome. |
| Q50056959 | Cardiometabolic Risk in PCOS: More than a Reproductive Disorder |
| Q37077315 | Cardiometabolic features of polycystic ovary syndrome |
| Q55437110 | Cardiometabolic risk in polycystic ovary syndrome. |
| Q42923822 | Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria |
| Q33655058 | Cardiovascular risk factors among women with self-reported infertility |
| Q37799892 | Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome |
| Q37539607 | Changes in HbA1c and circulating and adipose tissue androgen levels in overweight-obese women with polycystic ovary syndrome in response to electroacupuncture |
| Q33831357 | Cigarette smoking, nicotine levels and increased risk for metabolic syndrome in women with polycystic ovary syndrome |
| Q37115835 | Circulating levels and subcutaneous adipose tissue gene expression of pigment epithelium-derived factor in polycystic ovary syndrome and normal women: a case control study |
| Q38776405 | Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome |
| Q92024544 | Comparison of Two Statistical Methods to Determine Normal Range of Androgen Hormones: K-Means Cluster Analysis and Receiver Operating Characteristic Curve |
| Q50880377 | Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome. |
| Q24645442 | Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series |
| Q33587845 | Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline |
| Q36690960 | Diagnostic criteria for polycystic ovarian syndrome |
| Q51450568 | Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. |
| Q45958344 | Differential effects of walnuts vs almonds on improving metabolic and endocrine parameters in PCOS. |
| Q34390789 | Does polycystic ovary syndrome itself have additional effect on apelin levels? |
| Q35323904 | Effect of Treatment with Metformin on Omentin-1, Ghrelin and other Biochemical, Clinical Features in PCOS Patients |
| Q91918536 | Effects of Body Mass Index and Biochemical Lipid Levels on Reproductive Outcomes during An Intracytoplasmic Sperm Injection: A Retrospective Study |
| Q37307972 | Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome |
| Q36865823 | Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys |
| Q38085447 | Endocrine changes (beyond diabetes) after bariatric surgery in adult life. |
| Q37547069 | Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. |
| Q51743813 | Evaluation of Meibomian Gland Dysfunction in Polycystic Ovary Syndrome and Obesity. |
| Q51535448 | Evaluation of arterial blood pressure and renal sodium handling in a model of female rats in persistent estrus. |
| Q35108260 | Evidence for increased cardiovascular events in the fathers but not mothers of women with polycystic ovary syndrome |
| Q38420503 | Excess mortality in mothers of patients with polycystic ovary syndrome |
| Q37787632 | Exercise therapy in polycystic ovary syndrome: a systematic review |
| Q64237430 | Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis |
| Q84484303 | Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome |
| Q36607455 | Familial aggregation of circulating C-reactive protein in polycystic ovary syndrome |
| Q38332049 | Female-specific factors for IHD: across the reproductive lifespan |
| Q92461819 | Fertility Treatment Options for Women With Polycystic Ovary Syndrome |
| Q53808638 | Free androgen index and Irisin in polycystic ovary syndrome. |
| Q43739691 | Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. |
| Q36150037 | Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling |
| Q92533930 | Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives |
| Q38124916 | Genetic investigation into ethnic disparity in polycystic ovarian syndrome |
| Q90610702 | Genetics and Epigenetics of Infertility and Treatments on Outcomes |
| Q37678520 | Gonadal dysfunction in morbidly obese adolescent girls |
| Q40414974 | Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study. |
| Q44411292 | Haplotype TGTG from SNP 45T/G and 276G/T of the adiponectin gene contributes to risk of polycystic ovary syndrome |
| Q42759522 | Hepatic Steatosis is Common in Adolescents with Obesity and PCOS and Relates to De Novo Lipogenesis but not Insulin Resistance |
| Q35573208 | How does acupuncture affect insulin sensitivity in women with polycystic ovary syndrome and insulin resistance? Study protocol of a prospective pilot study |
| Q39179187 | How does obesity affect the endocrine system? A narrative review |
| Q45974242 | Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance. |
| Q33682425 | Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition |
| Q26822584 | Hyperandrogenism after menopause |
| Q41646937 | Hypertension in Reproductive-Aged Women With Polycystic Ovary Syndrome and Association With Obesity |
| Q36597107 | Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation induction |
| Q34099068 | Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis |
| Q36127665 | Increased body mass index negatively impacts blastocyst formation rate in normal responders undergoing in vitro fertilization. |
| Q51039118 | Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate. |
| Q55663899 | Influence of peroxisome proliferator-activated receptor-γ exon 2 and exon 6 and insulin receptor substrate (IRS)-1 Gly972Arg polymorphisms on insulin resistance and beta-cell function in southern mediterranean women with polycystic ovary syndrome. |
| Q35967487 | Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase |
| Q33728447 | Insulin resistance according to β-cell function in women with polycystic ovary syndrome and normal glucose tolerance |
| Q33569169 | Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications |
| Q35072207 | Insulin resistance influences central opioid activity in polycystic ovary syndrome |
| Q37565702 | Insulin resistance: the possible link between gestational diabetes mellitus and hypertensive disorders of pregnancy |
| Q24197673 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility |
| Q24240501 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility |
| Q24240654 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility |
| Q47402228 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. |
| Q24240263 | Insulin-sensitising drugs for polycystic ovary syndrome |
| Q37122614 | Kapalabhati pranayama: An answer to modern day polycystic ovarian syndrome and coexisting metabolic syndrome? |
| Q35769099 | Leptin as well as Free Leptin Receptor Is Associated with Polycystic Ovary Syndrome in Young Women |
| Q24242021 | Lifestyle changes in women with Polycystic Ovary Syndrome |
| Q92676368 | Lifestyle changes in women with polycystic ovary syndrome |
| Q24234000 | Lifestyle changes in women with polycystic ovary syndrome |
| Q24235398 | Lifestyle changes in women with polycystic ovary syndrome |
| Q34011105 | Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. |
| Q35200094 | Longterm management of Polycystic Ovarian Syndrome (PCOS) |
| Q53134066 | Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis. |
| Q40680864 | Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions |
| Q51375186 | Melatonin receptor 1A gene polymorphism associated with polycystic ovary syndrome. |
| Q37198401 | Menstrual health and the metabolic syndrome in adolescents |
| Q34379717 | Menstrual pattern and menstrual disorders among adolescents: an update of the Italian data |
| Q53714426 | Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. |
| Q37715436 | Metabolic Evidence of Diminished Lipid Oxidation in Women With Polycystic Ovary Syndrome |
| Q37362881 | Metabolic Syndrome and Its Characteristics among Reproductive-Aged Women with Polycystic Ovary Syndrome: A Cross-sectional Study in Northwest Iran |
| Q51475525 | Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. |
| Q38949684 | Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges |
| Q37412812 | Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. |
| Q36718602 | Metabolic syndrome and cardiometabolic risk in PCOS. |
| Q37494304 | Metabolic syndrome and polycystic ovary syndrome... and vice versa |
| Q40890622 | Metabolic syndrome in infertile women with polycystic ovarian syndrome. |
| Q46952697 | Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors |
| Q33569099 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study |
| Q91130000 | Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women |
| Q48006996 | Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome |
| Q38650624 | Modified Ferriman-Gallwey Score in Hirsutism and its Association with Metabolic Syndrome |
| Q51016078 | NMR Metabolomics Show Evidence for Mitochondrial Oxidative Stress in a Mouse Model of Polycystic Ovary Syndrome. |
| Q26829385 | Nonhuman primate models of polycystic ovary syndrome |
| Q27000954 | Obesity and PCOS: implications for diagnosis and treatment |
| Q51399542 | Obesity and insulin resistance in women with polycystic ovary syndrome. |
| Q50951899 | Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome. |
| Q38024326 | Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis |
| Q37092199 | PCOS Forum: research in polycystic ovary syndrome today and tomorrow |
| Q58759504 | Pharmacological sympathetic denervation prevents the development of polycystic ovarian syndrome in rats injected with estradiol valerate |
| Q33787190 | Pharmacotherapy of polycystic ovary syndrome--an update |
| Q36759686 | Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS? |
| Q35075035 | Polycystic Ovary Syndrome in the Pediatric Population |
| Q65954080 | Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health |
| Q80844876 | Polycystic ovary syndrome |
| Q35026437 | Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorder |
| Q90837412 | Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies |
| Q37699367 | Polycystic ovary syndrome and weight management |
| Q39393050 | Polycystic ovary syndrome, adipose tissue and metabolic syndrome |
| Q37347738 | Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies |
| Q35100161 | Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth |
| Q21245262 | Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan |
| Q37857735 | Polycystic ovary syndrome: a dermatologic approach |
| Q51724086 | Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15-25 years after ovarian wedge resection. |
| Q35119580 | Polycystic ovary syndrome: aggressive or protective factor for the retina? Evaluation of macular thickness and retinal nerve fiber layers using high-definition optical coherence tomography |
| Q37832125 | Polycystic ovary syndrome: etiology, pathogenesis and diagnosis |
| Q90020873 | Precocious subcutaneous abdominal stem cell development to adipocytes in normal-weight women with polycystic ovary syndrome |
| Q37611284 | Prediction of metabolic syndrome in women with polycystic ovary syndrome |
| Q36732197 | Predictors of insulin resistance and metabolic complications in polycystic ovarian syndrome in an eastern Indian population |
| Q33954314 | Pregnancy complicated by obesity induces global transcript expression alterations in visceral and subcutaneous fat. |
| Q37061257 | Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome |
| Q36406472 | Prevalence of metabolic syndrome in relation to body mass index and polycystic ovarian syndrome in Indian women |
| Q39011536 | Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. |
| Q38101206 | Rapid and easy assessment of insulin resistance contributes to early detection of polycystic ovary syndrome |
| Q26827236 | Recent advances in cardiovascular aspects of polycystic ovary syndrome |
| Q45168757 | Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome |
| Q83974723 | Relative associations of polycystic ovarian syndrome vs metabolic syndrome with thyroid function, volume, nodularity and autoimmunity |
| Q37360333 | Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells |
| Q28390200 | Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome |
| Q36223775 | Serum Copeptin, Pentraxin 3, Anti-Mullerian Hormone Levels With Echocardiography and Carotid Artery Intima-Media Thickness in Adolescents With Polycystic Ovary Syndrome |
| Q43668598 | Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome |
| Q30423117 | Should all women with PCOS be treated for insulin resistance? |
| Q35233754 | State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). |
| Q89733605 | State of the Science in Women's Cardiovascular Disease: A Canadian Perspective on the Influence of Sex and Gender |
| Q36201532 | Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility |
| Q35688517 | Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome |
| Q41856851 | Tailoring cardiovascular risk assessment and prevention for women: One size does not fit all. |
| Q36943683 | Targets to treat metabolic syndrome in polycystic ovary syndrome |
| Q49805806 | Ten Years of Experience in Contraception Options for Teenagers in a Family Planning Center in Thrace and Review of the Literature |
| Q37016343 | Testosterone, diabetes mellitus, and the metabolic syndrome |
| Q28394688 | The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial |
| Q38832462 | The Role of Physical Activity in Preconception, Pregnancy and Postpartum Health. |
| Q34190360 | The comparison of insulin resistance frequency in patients with recurrent early pregnancy loss to normal individuals |
| Q38056783 | The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis |
| Q37326585 | The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review |
| Q40771483 | The impact of insulin resistance on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome |
| Q37989176 | The link between polycystic ovary syndrome and both Type 1 and Type 2 diabetes mellitus: what do we know today? |
| Q33569142 | The metabolic syndrome |
| Q37362674 | The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? |
| Q43255172 | The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome |
| Q34262427 | The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance |
| Q39641963 | The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome |
| Q34761179 | The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study |
| Q43119904 | The role of chronic inflammation and Leu55Met PON1 polymorphism in the pathogenesis of polycystic ovary syndrome |
| Q35610387 | The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment |
| Q36697482 | Tissue-selective regulation of androgen-responsive genes |
| Q35770685 | Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study |
| Q37231872 | Triglycerides to High-Density Lipoprotein Cholesterol Ratio Can Predict Impaired Glucose Tolerance in Young Women with Polycystic Ovary Syndrome |
| Q37764078 | Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? |
| Q36069769 | Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry |
| Q79566798 | [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome] |
Search more.